InvestorsHub Logo
Followers 1053
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

Re: None

Friday, 10/17/2014 5:40:34 AM

Friday, October 17, 2014 5:40:34 AM

Post# of 27563
iBio, Inc. (IBIO) confirmed the applicability of its issued U.S. iBioLaunch(TM) platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus.

IBIO has offered to assist the U.S. government by making its proprietary technology available for emergency use to enable the manufacture and yield optimization of certain experimental antibody-based drugs that address the current Ebola virus outbreak, to the extent such assistance is requested by the government.

IBIO owns the iBioLaunch(TM) platform, which is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.

More about iBio, Inc. (IBIO) at www.ibioinc.com.

http://www.live-pr.com/en/drama-ebola-scenario-sarepta-therapeutics-inc-r1050484579.htm

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IBIO News